Findings

What do systematic reviews say?

21 questions · 21 findings · 1 reviews · Urology

No studies found 6 · 28.6%GRADE not reported 0 · 0%Very low 6 · 28.6%Low 9 · 42.9%Moderate 0 · 0%High 0 · 0%

Time to progression · patients with non‐muscle invasive bladder cancer

Gemcitabine showed no clear difference in time to progression compared with mitomycin (low certainty).

1 finding from 1 review

Intravesical gemcitabine for non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
HR 0.57 [0.32, 1.01]
1 study · 109 participants
Low